Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 12,001–12,100 of 15,747
The Clinical Impact of SARS-CoV-2 on Hypertrophic Cardiomyopathy
Saleh, D., Meng, Z., Johnson, N. A., Baldridge, A. S., Zielinski, A. R., & Choudhury, L. (2024) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd11040104 · Cited by 5
“The study interval (1 January 2019 through 1 January 2021) predates the emergence of herd immunity within the population and/or the availability of the COVID-19 vaccines which have been shown to protect against COVID-19-related illness [21–23].”
BackgroundComparative Analysis of Vaccines and Probiotics in Fighting the Covid19
Belojević, G. (2021) · Biomedical Journal of Scientific & Technical Research · doi:10.26717/bjstr.2021.34.005487 · Cited by 2
Modelling the impact of hybrid immunity on future COVID-19 epidemic wavesPreprint
Le, T. P., Abell, I. R., Conway, E. J., Campbell, P. T., Hogan, A. B., Lydeamore, M., McVernon, J., Müeller, I., Walker, C. R., & Baker, C. M. (2023) · medRxiv · doi:10.1101/2023.03.12.23287174 · Cited by 2
Monoclonal antibodies for the treatment of COVID-19 infection in children
Ling, K. M., & Dougan, M. L. (2022) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2022.2134117 · Cited by 2
Venuto, R., Giunta, I., Vaccaro, M., Fauci, V. L., Ceccio, C., Fedele, F., Privitera, A. C., Denaro, F., Pantò, G., Cortese, R., et al. (2022) · Vaccines · doi:10.3390/vaccines10111803 · Cited by 2
“A similar result was obtained by a Spanish randomized study enrolling subjects aged between 18 and 60 years, who received a dose of Comirnaty 2–3 months after the priming with Vaxzevria [13,14].”
ResultCoronaviruses: Pandemic SARS-CoV-2
Cowling, B. J., & Wong, S. (2024) · Springer eBooks · doi:10.1007/978-1-4939-9544-8_68-1 · Cited by 2
Madibana, M. J., Fouché, C. H., & Manyeula, F. (2024) · African Journal of Food Agriculture Nutrition and Development · doi:10.18697/ajfand.127.23290 · Cited by 2
(2022) · doi:10.1101/2022.01.27.22269944 · Cited by 2
“All participants followed standard clinical practice by their treating neurologist and interval of time between second and third vaccination was not standardised(16, 17).”
BackgroundBrown, J. P., Mook, P., Vanhaverbeke, M., Gimma, A., Hagan, J. E., Singini, I. L., Avdičová, M., Cullen, G., Dotsenko, L., Mossong, J., et al. (2025) · Epidemiology and Infection · doi:10.1017/s0950268824001833 · Cited by 2
“[1,2] However, some real-world effectiveness estimates are lower and there is evidence that the effectiveness of currently licensed COVID-19 vaccines against infection may be lower against more recent circulating SARS-CoV-2 variants of concern (VOC).”
The association between CD46 expression in B cells and the pathogenesis of airway allergy
Geng, X., Xue, J., Zheng, H., Suo, L., Zeng, H., Zhao, M., Song, S., Liu, Y., Zhao, C., & Yang, P. (2023) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2023.166845 · Cited by 1
Pedersen, A. L. D., Wood, G., Frederiksen, C. A., Løgstrup, B. B., Jensen, M. K., Østergaard, L. J., Kim, W. Y., & Poulsen, S. H. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.964412 · Cited by 3
Wu, Y., Jia, X., Wu, N., Zhang, X., Wu, Y., Liu, Y., Zhou, M., Shen, Y., Li, E., Wang, W., et al. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.12.030 · Cited by 2
Luan, N., Huang, L., Hu, J., Zhang, H., Gao, D., Lei, Z., Zhang, X., Cao, H., & Liu, C. (2025) · Vaccines · doi:10.3390/vaccines13040361 · Cited by 3
“The success of mRNA vaccines has been demonstrated by COVID-19 mRNA vaccines, including BNT162b2 and mRNA-1273 [7,8].”
Antwi, K., Caobelli, F., Kudura, K., et al. (2022) · Diagnostics · doi:10.3390/diagnostics12123073 · Cited by 2
“3% of subjects receiving the BNT162b2 vaccine according to data from physical examination [8].”
BackgroundIntroduction to COVID-19 Vaccines and Kidney Transplant Recipient
Israr, J., & Kumar, A. (2025) · OBM Transplantation · doi:10.21926/obm.transplant.2501236 · Cited by 4
Murata, M., Matsumoto, Y., & Shimono, N. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.127457 · Cited by 3
Li, S., Zheng, L., Zhang, Z., Zhang, J., Liu, X., Xu, J., Yang, R. L., Yang, Y., Zhao, Y., Zhong, J., et al. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114482 · Cited by 5
SARS-CoV-2 dynamics in New York City during March 2020–August 2023
Yang, W., Parton, H. B., Li, W., Watts, E. A., Lee, E., & Yuan, H. (2025) · Communications Medicine · doi:10.1038/s43856-025-00826-6 · Cited by 2
Immunogenicity and Safety of BNT162b2 mRNA Vaccine in Chinese Adults: A Randomized Clinical TrialPreprint
Hui, A., Li, J., Zhu, L., Tang, R., Ye, H., Lin, M., Ge, L., Wang, X., Peng, F., Wu, Z., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4114061 · Cited by 2
Self-citationDiscovEpi: automated whole proteome MHC-I-epitope prediction and visualization
Mahncke, C., Schmiedeke, F., Simm, S., et al. (2024) · BMC Bioinformatics · doi:10.1186/s12859-024-05931-2 · Cited by 2
“For better resolution of the display we limited the sequence length to 1300 amino acids to still display the full glycoprotein SPIKE_SARS2 which is already used in vaccines [19] at the expense of truncated sequences of the two replicase proteins R1A_SARS2 and R1AB_SARS2 (Fig.”
BackgroundDevelopment of Accurate Long-lead COVID-19 Forecast
Yang, W., & Shaman, J. L. (2023) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1011278 · Cited by 3
Particulate vaccines against SARS-CoV-2
García-Soto, M. J., Farfán-Castro, S., Wong-Arce, A., Romero‐Maldonado, A., González‐Ortega, O., & Rosales‐Mendoza, S. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-90248-9.00009-7 · Cited by 2
Mavridis, C., Aidonidis, G., & Kalogeridis, A. (2022) · Qeios · doi:10.32388/h4xgp2.6
Myocarditis after COVID-19 mRNA vaccination in Norway: a nationwide validation study
Hagen, B. S., Vlaisavljevic, K. V. K., Oppedal, L. S., Endresen, J., Mohn, V., Fladseth, K., Lysaker, T. M., Ribe, M. P., Möller, T. F., Hole, T., et al. (2026) · Open Heart · doi:10.1136/openhrt-2026-004112 · Cited by 1
Effet placebo ? Effet nocebo ? Qu’en sait-on ?
Casassus, P. (2021) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2021.01.012 · Cited by 5
Long-term immune response to mRNA anti-SARS-CoV-2 vaccination in patients with cancer
Lobo-Martins, S., Martins-Branco, D. A., Padonou, F., Dahma, H., den Wijngaert, S. V., Jaouart, M., Dauccia, C., Molinelli, C., Agostinetto, E., Loizidou, A., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1815933 · Cited by 1
Rehms, R., Ellenbach, N., Rehfuess, E. A., et al. (2022) · medRxiv · doi:10.1101/2022.06.20.22276652 · Cited by 1
“For βvacc1 and βvacc2 we chose 0.6 and 0.3 respectively to reflect the heterogeneity in the used vaccinations and uncertainty over the actual effect (Pritchard et al., 2021; Voysey et al., 2021; Keehner et al., 2021; Polack et al., 2020; Baden et al., 2021).”
InfluentialDiego, J. G., Singh, G., Jangra, S., Handrejk, K., Laporte, M., Chang, L. A., Zahed, S. E. E., Pache, L., Chang, M. W., Warang, P., et al. (2023) · bioRxiv · doi:10.1101/2023.05.22.541294
Bellizzi, V., Fordellone, M., Secondulfo, C., Chiodini, P., & Bilancio, G. (2025) · Vaccines · doi:10.3390/vaccines13060566 · Cited by 1
Oka, M., Fujii, Y., & Murakami, S. (2024) · Dermatologic Therapy · doi:10.1155/2024/2777924 · Cited by 1
Dua, A., Roshan, R., Nigam, A., Yadav, D., & Chaudhary, J. K. (2023) · Microsphere · doi:10.59118/xlok1140 · Cited by 1
The landscape of genetic medicines for in vivo T cell reprogramming
(1953121), J. B. S., Lemgart, V. T., Kulkarni, J. A., & Witzigmann, D. (2026) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2026.115940 · Cited by 1
Jana, I. D., Kanjo, K., Roy, S., Bhasin, M., Bhattacharya, S., Banerjee, I., Jana, S., Chatterjee, A., Chakraborty, A., Chakraborty, S. K., et al. (2025) · Journal of Virology · doi:10.1128/jvi.00051-25 · Cited by 1
Purba, G. C. F., Gatot, D., & Syahrini, H. (2022) · International Journal of Research and Review · doi:10.52403/ijrr.20220865
Mörl, F., Gunther, M. M., & Rockenfeller, R. (2023) · International Journal of Vaccine Theory Practice and Research · doi:10.56098/s9cjk650 · Cited by 1
“The latter researchers, however, had analyzed just a specific selection of serious AEs in the original data of two phase-3 clinical trials (showing harm-to-benefit ratios above 1 in both of the most used SARS-CoV-2 vaccines: 4.4 in BNT162b2 by Pfizer and 2.4 in mRNA-1273 by Moderna).”
MethodResultInfluentialBarmpounakis, P., Demiris, N., Kontoyiannis, I., et al. (2021) · medRxiv · doi:10.1101/2021.05.19.21257486 · Cited by 1
Saroyo, Y. B. (2021) · Indonesian Journal of Obstetrics and Gynecology · doi:10.32771/inajog.v9i1.1495 · Cited by 1
Nucleic acid-based vaccines of COVID-19 and their delivery systems
Yang, H., Zhang, M., Weng, Y., Cao, Y., & Huang, Y. (2021) · Scientia Sinica Vitae · doi:10.1360/ssv-2021-0051 · Cited by 1
COVID-19 in Children and COVID-19 Vaccines
Whittaker, E., & Heath, P. T. (2021) · Springer eBooks · doi:10.1007/978-3-030-77173-7_27 · Cited by 1
Jeulin, H., Craus, D., Labat, C., & Benetos, A. (2021) · medRxiv · doi:10.1101/2021.08.03.21261014 · Cited by 1
Body, A. L., Milch, V., McSorley, L. M., et al. (2022) · Vaccines · doi:10.3390/vaccines10122003 · Cited by 1
Banerjee, M., Chadha, S., Sanyal, S., & Mukherjee, S. (2023) · Coronaviruses · doi:10.2174/0126667975269506231108053010 · Cited by 2
A novel approach to designing viral precision vaccines applied to SARS-CoV-2
Trabelsi, K., Khalaf, N. B., Ramadan, A. R., Elsharkawy, A., Ashoor, D., Chlif, S., Boussoffara, T., Ahmed, M. B., Kumar, M., & Fathallah, M. D. (2024) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2024.1346349 · Cited by 1
Myocarditis and COVID-19 related issues
Ciabatti, M., Zocchi, C., Olivotto, I., Bolognese, L., & Pieroni, M. (2023) · Global Cardiology Science and Practice · doi:10.21542/gcsp.2023.28 · Cited by 1
Current treatments and the future of nanomedicine in hepatitis C
Julien, D., & Bach, H. (2025) · Nanomedicine · doi:10.1080/17435889.2025.2518912 · Cited by 1
Contributions of immigrants to biomedical research in the US: a personal reflection
Paczesny, S. (2021) · Journal of Clinical Investigation · doi:10.1172/jci148994 · Cited by 1
Considerations for Using Clinical Practice Data to Study COVID-19 Vaccines in Patients With Cancer
Han, L. (2025) · JAMA Oncology · doi:10.1001/jamaoncol.2025.1937 · Cited by 1
García-Pelagio, K. P., Hew‐Butler, T., FAHLMAN, M. M., & Roche, J. A. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph181910271 · Cited by 2
Oka, M. (2025) · Acta Dermato Venereologica · doi:10.2340/actadv.v105.42546 · Cited by 1
Tri, A., Mills, K., & Nilsen, K. M. (2022) · Kansas Journal of Medicine · doi:10.17161/kjm.vol15.18431 · Cited by 1
COVID-19 Vaccine-induced antibody response to BNT162b2 mRNA in frontline healthcare workers
Serrano, N. C., Mejía, C. C. C., Bautista‐Niño, P. K., Suárez, D. P. S., Acosta, I. S., García, A. Y. S., Meneses, L., Sopó-Rincón, O. L., & Quintero-Lesmes, D. C. (2024) · Salud UIS · doi:10.18273/saluduis.56.e:24034 · Cited by 1
“The immune response of the BNT162b2 vaccine is directed against the SARS-CoV-2 S1 spike protein, and the antibody titers are associated with the functional neutralization of the virus 1 .”
Vacunas para Covid-19: seguridad, elaboración y distribución
Medrano, N. B., Simancas‐Racines, D., & Guevara, C. M. M. (2021) · Práctica Familiar Rural · doi:10.23936/pfr.v6i2.206 · Cited by 6
“BioNTech/Pfizer (21,22,23) 2 con 21 días de intervalo entre ambas ≥ 12 años Dolor, enrojecimiento, hinchazón Fatiga, escalofríos, dolor de cabeza”
BackgroundMicrofluidic Device Type Improves Heart mRNA Delivery In Vivo
Echeverri, E. S., Kim, H., Jang, B., Shakked, A., Park, C. J., Baek, K. I., Choi, L., Kang, D. W., Hung, R.-C., Jeong, K., et al. (2025) · Langmuir · doi:10.1021/acs.langmuir.5c02612 · Cited by 1
A large survey on COVID-19 vaccination in patients with Parkinson’s disease and healthy population
Han, C., Zhao, Z., Chan, P., Li, F., Chi, C. L., Zhang, X., Zhao, Y., Chen, J., & Hong, J. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.09.002 · Cited by 1
Predicting the Effectiveness of Covid-19 Vaccines from SARS-CoV-2 Variants Neutralisation DataPreprint
Volkov, O., Borozdenkova, S., & Gray, A. (2021) · medRxiv · doi:10.1101/2021.09.06.21263160 · Cited by 1
“To model symptomatic vaccine effectiveness we used its estimates from the Pfizer-BioNTech Phase 3 vaccine trial (FDA, 2020; Polack et al., 2020) and from seven large observational studies with the Comirnaty vaccine post-authorisation.”
MethodMiranda, M. C. R., Nunes, C. M., Losito, D. W., da Rocha, F. S., Pedro, J. A. F., Favoretto, B. C., Teobaldo, G. B. M., da Silva, L. C. C., Lopes, J. L. D. S., Oliveira, C. L. P., et al. (2025) · ACS Omega · doi:10.1021/acsomega.5c03459 · Cited by 1
The evaluation of vaccination status and the factors affecting vaccination in cancer patients
Ürün, M., Beypınar, İ., Davarcı, S. E., Demir, H., & Baykara, M. (2022) · Acta Medica Alanya · doi:10.30565/medalanya.1094182 · Cited by 1
Chuai, X., Zhao, B., Wu, Y., Zhou, J., Ye, T., Yang, Y., Wang, C., Li, F., Zhang, K., Hu, J., et al. (2026) · Journal of Nanobiotechnology · doi:10.1186/s12951-026-04557-1 · Cited by 1
“CircRNA was encapsulated in LNPs using a microfluidic device as previously described [32, 33].”
Next-Generation Nanoparticle-Enabled mRNA Vaccines in the Treatment of COVID-19
Kole, E. B., Jadhav, K., Singh, R., Verma, R. K., Chatterjee, A., & Naik, J. (2025) · Critical Reviews in Therapeutic Drug Carrier Systems · doi:10.1615/critrevtherdrugcarriersyst.2025053265 · Cited by 2
Palacka, P., Svobodová, A., Skokanová, L., Obertová, J., Rejleková, K., Babela, R., Mego, M., Vulganova, M., & Pechan, J. (2023) · Preprints.org · doi:10.20944/preprints202309.0842.v1 · Cited by 1
Tan, E. X. X., Lim, W. H., Thong, E. H., Chavatte, J., Zhang, J., Lim, J., Jin, J. Y., Lim, D. R. X., Kang, J. Y. T., Tang, A. S. P., et al. (2023) · Transplantation Direct · doi:10.1097/txd.0000000000001537 · Cited by 1
Ranawaka, N., & Welikumburab, N. H. (2021) · South Florida Journal of Health · doi:10.46981/sfjhv2n2-010 · Cited by 1
“Most of the countries start immunization programs for their population (6), (7).”
BackgroundTrimeric S protein COVID-19 vaccine needs to find its place
Vesikari, T. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00096-4 · Cited by 1
Liu, X., Qi, Y., Huang, T., Huang, L., Zhao, M.-X., Wang, Z., Dai, J., Wang, Y., Chen, J., Yang, X., et al. (2025) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2025.2502250 · Cited by 1
Biotechnology in Medicine: Fundamentals
Nigam, M., Singh, N., Dimri, D. B., & Mishra, A. P. (2025) · Interdisciplinary biotechnological advances · doi:10.1007/978-981-96-4959-4_1 · Cited by 2
Safety of and Adverse Reactions to the COVID-19 Vaccine Among Pregnant and Breastfeeding Women
Thanh, N. T. M., Hằng, L. T. T., Hung, M. T., Phuong, T. H., Lan, N. T. P., Tuan, M. D., Bach, N. X., & Anh, N. D. (2025) · Medical Sciences · doi:10.3390/medsci13020038 · Cited by 2
“Similar findings were reported by Fernando et al., who observed an increased risk of adverse reactions among individuals under 55 years of age, likely due to heightened immune responses to vaccination [23,24].”
Standardized Two-Step Testing of Antibody Activity in COVID-19 Convalescent PlasmaPreprint
Gilchuk, P., Thomsen, I. P., Yoder, S. M., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3878407 · Cited by 1
Lapuente, D., Fuchs, J., Willar, J., Antão, A. V., Eberlein, V., Uhlig, N., Issmail, L., Schmidt, A., Oltmanns, F., Peter, A. S., et al. (2021) · bioRxiv · doi:10.1101/2021.08.03.454858 · Cited by 6
Inaba, S., Ikeda, S., Fujiwara, Y., Sogabe, K., Inoue, K., Nogami, N., Ishii, E., & Yamaguchi, O. (2024) · Cureus · doi:10.7759/cureus.68749 · Cited by 1
A Case of Acute Pericarditis After COVID-19 Vaccination
Sonaglioni, A., Albini, A., Noonan, D. M., Brucato, A. L., Lombardo, M., & Santalucia, P. (2021) · Frontiers in Allergy · doi:10.3389/falgy.2021.733466 · Cited by 3
“It is known that a two-dose regimen of BNT162b2 confers 95% protection against Covid-19 and the safety profile is adequate (2).”
BackgroundMethodCOVID-19 Breakthrough Infections in Vaccinated Patients With CLL in Israel
Yekutiel, N., Chodick, G., Tene, L., et al. (2023) · HemaSphere · doi:10.1097/hs9.0000000000000839 · Cited by 1
Genomics, metagenomics, and pan-genomics approaches in COVID-19
Waseem, M., Basheer, A., Anwer, F., Shahid, F., Zaheer, T., & Ali, A. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-91794-0.00011-1 · Cited by 1
Gibson, S., Saunders, R., Stasko, N., Bickerstaff, C., Oakley, J., Osterman, M., Torres, R. T., Kish, J. K., Feinberg, B. A., & Emerson, D. (2022) · Journal of Medical Economics · doi:10.1080/13696998.2022.2055370 · Cited by 2
Diabetic Ketoacidosis After COVID-19 Vaccine in Patients with Type 1 Diabetes Mellitus
Albedaiwi, F. B., Alshammari, M. M., Algeffari, M., Alfouzan, A. A., Alfouzan, Y. A., Siddiq, H., & Hussein, O. (2023) · Intern J Endocrinol Metab · doi:10.5812/ijem-135866 · Cited by 1
“The researchers have monitored the short-term side effects of COVID-19 vaccination, which include fatigue, pain, fever, chills, headache, nausea, and vomiting (29-31).”
Chiang, M., Wang, J., Lin, W., Yen, R., Huang, J.-Y., & Lu, C. (2023) · European journal of medical research · doi:10.1186/s40001-023-01456-1 · Cited by 1
“Regional lymphadenopathy was reported in 0.3% of the recipients after the BNT162B2 vaccine, whose package leaflet classifies enlarged lymph nodes as an uncommon side effect [33].”
BackgroundInfluentialTariq, M. J., Noraldeen, M. Y., & Al-kadhi, N. A. (2023) · Medical Journal of Babylon · doi:10.4103/mjbl.mjbl_171_22 · Cited by 1
Can a second booster dose be delayed in patients who have had COVID-19?Preprint
Täubel, J., Spencer, C. S., Freier, A., Camilleri, D., Garitaonandia, I., & Lorch, U. (2021) · medRxiv · doi:10.1101/2021.04.09.21255200 · Cited by 1
Nanoparticles in Thyroid Autoimmunity: Diagnostic and Therapeutic Applications
Elia, G., Ferrari, S. M., Ragusa, F., Balestri, E., Botrini, C., Colapietra, F., Monica, P. D., Antonelli, A., Fallahi, P., & Domenico, M. D. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15041428 · Cited by 3
SARS-COV-2 Vaccine Responses in Renal Patient PopulationsPreprint
Smith, R., Cooper, D. J., Döffinger, R., Stacey, H., Al-Mohammad, A., Goodfellow, I., Baker, S. G., Lear, S. E., Hosmillo, M. D. T., Pritchard, N., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1202990/v1 · Cited by 1
Self-citationGillman, L., Suleski, D., Graham, M. E., Ginn, S. L., & Hassan, M. M. (2026) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.6c00618 · Cited by 2
Response to COVID-19 Vaccination in Patients with Inflammatory Bowel Disease on Biological Treatment
Bodini, G., Giuliana, E., Giberti, I., Guarona, G., Benvenuto, F., Ferretti, E., Demarzo, M. G., Rin, G. D., Icardi, G., & Giannini, E. G. (2022) · Gastrointestinal Disorders · doi:10.3390/gidisord4020009 · Cited by 1
“Lastly, as far as the safety profile of the COVID-19 vaccination in patients with IBD is concerned, the rate and degree of side effects to vaccination were consistent with those reported in the literature in subjects without IBD, and no new or unexpected side effects were observed [20].”
ResultSaito, T., Couzinet, A., Suzuki, T., Shimomura, M., Ryo, A., Miyakawa, K., Katayama, Y., & Nakatsura, T. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.127942 · Cited by 2
COVID-19 Animal Models and Vaccines: Current Landscape and Future Prospects
Wang, S., Li, L., Yan, F., Gao, Y., Yang, S., & Xia, X. (2021) · Vaccines · doi:10.3390/vaccines9101082 · Cited by 26
Siewert, B., Szabat, A., Chądzińska-Cebula, M., Purpurowicz-Miękus, N., Sujkowski, P., Spachacz, R., Dworacki, G., Wysocki, J., Januszkiewicz‐Lewandowska, D., & Gowin, E. (2022) · International Journal of Occupational Medicine and Environmental Health · doi:10.13075/ijomeh.1896.01887 · Cited by 2
Pfizer mRNA COVID-19 Vaccination and Acute Inflammatory Demyelinating Polyneuropathy
Bernardo, K. A., & Misra, A. (2022) · Journal of Clinical Neuromuscular Disease · doi:10.1097/cnd.0000000000000397 · Cited by 1
Suteja, R. C., Salim, A., Suryanov, I. P. D., Tirtayasa, P. M. W., & Duarsa, G. W. K. (2023) · Transplant Immunology · doi:10.1016/j.trim.2023.101902 · Cited by 2
Hirano, T., & Sato, F. (2022) · AIP conference proceedings · doi:10.1063/5.0119366 · Cited by 1
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.